Clinical

Dataset Information

0

A Retrospective Observational Study in the Expanded Access Program of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer (BEACON EAP Follow-up Study )

ABSTRACT: Primary outcome(s): Overall survival

DISEASE(S): Braf V600e-mutant Metastatic Colorectal Cancer

PROVIDER: 33441 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
| S-EPMC7260582 | biostudies-literature
Unknown Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
| S-EPMC9271503 | biostudies-literature
Unknown Encorafenib plus cetuximab for the treatment of <i>BRAF-V600E</i>-mutated metastatic colorectal cancer.
| S-EPMC9260564 | biostudies-literature
Unknown Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.
| S-EPMC9271477 | biostudies-literature
Clinical Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer
| 2745961 | ecrin-mdr-crc
Unknown Development of encorafenib for BRAF-mutated advanced melanoma.
| S-EPMC5815646 | biostudies-literature
Unknown Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.
| S-EPMC7370699 | biostudies-literature
Transcriptomics Sarcoidosis + Follow-up study
2005-01-18 | GSE1907 | GEO
Unknown Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
| S-EPMC7004095 | biostudies-literature
Unknown Efficacy and Safety Results of the Afatinib Expanded Access Program.
| S-EPMC5488108 | biostudies-literature